Identification of 5-HT3 receptors on human platelets: Increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP)

Thrombosis and Haemostasis

Volumn 99, Issue 4, 2008, Pages 784-786

  Stratz, Christian ^a   Trenk, Dietmar ^a   Bhatia, Harsharan S ^b   Valina, Christian ^a   Neumann, Franz Josef ^a   Fiebich, Bernd L ^b  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE KINASE; SEROTONIN 3 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

IMMUNOMODULATION; IMMUNOREACTIVITY; LETTER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; THROMBOCYTE; WESTERN BLOTTING;

ACID PHOSPHATASE; ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CELL MEMBRANE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; PLATELET ACTIVATION; RECEPTORS, SEROTONIN, 5-HT3;

EID: 43749106281     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-10-0630     Document Type: Letter

References (19)

1. Li N, Wallen NH, Ladjevardi M, et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-523.
2. De Clerck F, Xhonneux B, Leysen J, et al. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 33: 2807-2811.
3. Cerrito F, Lazzaro MP, Gaudio E, et al. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993; 53: 209-215.
4. Fiebich BL, Akundi RS, Seidel M, et al. Expression of 5-HT3A receptors in cells of the immune system. Scand J Rheumatol 2004; (Suppl): 9-11.
5. Fiebich BL, Akundi RS, Lieb K, et al. Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol 2004; (Suppl): 28-32.
6. Vega LL, Munoz E, Calzado MA, et al. The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem Pharmacol 2005; 70: 369-380.
7. Werner P, Kawashima E, Reid J, et al. Organization of the mouse 5-HT3 receptor gene and functional expression of two splice variants. Brain Res Mol Brain Res 1994; 26: 233-241.
8. Maricq AV, Peterson AS, Brake AJ, et al. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991; 254: 432-437.
9. Reeves DC, Lummis SC. The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review). Mol Membr Biol 2002; 19: 11-26.
10. Niesler B, Frank B, Kapeller J, et al. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003; 310: 101-111.
11. Greenshaw AJ, Silverstone PH. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications. Drugs 1997; 53: 20-39.
12. Fatima SK. Effect of D-serine on the serotonin receptors of human platelets. Exp Brain Res 2006; 173: 353-356.
13. Weyrich A, Cipollone F, Mezzetti A, et al. Platelets in atherothrombosis: new and evolving roles. Curr Pharm Des 2007; 13: 1685-1691.
14. Steinhubl SR. Platelets as mediators of inflammation. Hematol Oncol Clin North Am 2007; 21: 115-121.
15. Michiels JJ, Gawaz M. Preface: platelets in inflammation and atherothrombosis. Semin Thromb Hemost 2007; 33: 119-122.
16. Schneider EM, Ma X, Stratz T, et al. Immunomodulatory function of the 5-HT3 receptor antagonist tropisetron. Scand J Rheumatol 2004; (Suppl): 34-40.
17. Muller W, Fiebich BL, Stratz T. 5-HT3 receptor antagonists als analgetics in rheumatic diseases. Z Rheumatol 2006; 65: 546, 548-552.
18. Walther DJ, Peter JU, Winter S, et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-862.
19. Berry CN, Lorrain J, Lochot S, et al. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Thromb Haemost 2001; 85: 521-528.